Merck KGaA said on Tuesday that Allan Gabor will succeed Alasdair Jelfs as managing director for the company in China as of Feb. 1, 2018.
The German company said Mr. Gabor would also take over operational responsibility for the performance materials business in China.
Additionally, Mr. Gabor will become a permanent member of the performance materials leadership team, Merck KGaA said.
Mr. Jelfs take up duties at company headquarters in Darmstadt, Germany, the company said.
Mr. Gabor joined Merck KGaA in 2013, and is currently head of the biopharma business in Asia, including China. Prior to joining the company, Mr. Gabor was head of Pfizer in China.
By Marc Navarro Gonzalez
Source: Dow Jones Newswires via Fox Business
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.